User removed 4
New member
yes thats exactly what i was implying, but i cant see where i have given the impression that the drug companies should be given a blank cheque.You seem to be implying that patients with long term illnesses are not getting the necessary drugs because of NHS cash restraints. My view is that the costs of new treatments has often been set deliberately and unnecessarily high in the UK and that is why many of these drugs, whether experimental or not, are not readily available on the NHS. The pharmaceutical industry has, until recently, been generally unwilling to accept that drug cost has any relevance in what should be provided and never (imo) engaged in any meaningful discussion with the DoH on this, particularly involving any cost vs clinical outcome measurement. That's why NICE, for all its shortcomings, was set up.